diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM2015142-47diaendo-6697Research ArticleГенетикаGeneticsОтсутствие ассоциации полиморфных локусов rs5219 гена KCNJ11 и rs757110 гена ABCC8 с долгосрочным ответом на терапию препаратами сульфонилмочевины в Новосибирской областиLack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk regionБондарьИрина АркадьевнаBondarIrina Arkad'evna

доктор медицинских наук, профессор, заведующий кафедрой эндокринологии

MD, PhD, Professor, Cheif of the Endocrinology Chair

bondaria@oblmed.nsk.ruФилипенкоМаксим ЛеонидовичFilipenkoMaksim Leonidovich

кандидат биологических наук, руководитель лаборатории «Фармакогеномики»

PhD, Head of the pharmacogenomic laboratory

mlfilipenko@gmail.comШабельниковаОлеся ЮрьевнаShabel'nikovaOlesya Yur'evna

кандидат медицинских наук, руководитель областного эндокринологического центра, ассистент кафедры эндокринологии

MD, PhD, Head of the Regional diabetes centre

oushab@ngs.ruСоколоваЕкатерина АлексеевнаSokolovaEkaterina Alexeevna

инженер лаборатории «Фармакогеномики»

engineer of the pharmacogenomic laboratory

sokolovaea2608@gmail.comГБОУ ВПО «Новосибирский Государственный медицинский университет» Минзрава России, НовосибирскРоссияNovosibirsk State Medical University, NovosibirskRussian FederationФГБУН «Институт химической биологии и фундаментальной медицины» СО РАН, Новосибирск; ФГБОУ ВПО "Новосибирский национальный исследовательский государственный университет", НовосибирскРоссияInstitute of Chemical Biology and Fundamental Medicine, Novosibirsk; Novosibirsk State University, NovosibirskRussian FederationГБУЗ НСО "Государственная Новосибирская областная клиническая больница", Новосибирск; ГБОУ ВПО «Новосибирский Государственный медицинский университет» Минзрава России, НовосибирскРоссияInstitute of Chemical Biology and Fundamental Medicine, Novosibirsk; Novosibirsk State University, NovosibirskRussian FederationФГБУН «Институт химической биологии и фундаментальной медицины» СО РАН, Новосибирск; ФГБОУ ВПО "Новосибирский национальный исследовательский государственный университет", НовосибирскРоссияNovosibirsk State Medical University, Novosibirsk; Novosibirsk State Regional Hospital, NovosibirskRussian Federation2015180320151814247Copyright © Бондарь И.А., Филипенко М.Л., Шабельникова О.Ю., Соколова Е.А., 20152015Бондарь И.А., Филипенко М.Л., Шабельникова О.Ю., Соколова Е.А.Bondar I.A., Filipenko M.L., Shabel'nikova O.Y., Sokolova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6697сахарный диабет 2 типаинсулинорезистентностьфармакогенетикапрепараты сульфонилмочевиныKCNJ11 (rs5219)ABCC8 (rs757110)type 2 diabetes mellituspharmacogenomicsinsulin resistancesulfonylureasKCNJ11 (rs5219)ABCC8 (rs757110)Российский Фонд Фундаментальных ИсследованийReferencesOECD. Health at a Glance: Europe 2012. OECD Publishing; 2012.OECD. Health at a Glance: Europe 2012. OECD Publishing; 2012.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0International Diabetes Federation treatment algorithm for people with type 2 diabetes. 2012. Available from: http://www.idf.otg/Global_guideline/International Diabetes Federation treatment algorithm for people with type 2 diabetes. 2012. Available from: http://www.idf.otg/Global_guideline/Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes, obesity & metabolism. 2008;10 Suppl 1:1–7. doi: 10.1111/j.1463-1326.2008.00884.x.Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes, obesity & metabolism. 2008;10 Suppl 1:1–7. doi: 10.1111/j.1463-1326.2008.00884.x.Best JD, Drury PL, Davis TM, et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes care. 2012;35(5):1165–1170. doi: 10.2337/dc11-1307Best JD, Drury PL, Davis TM, et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes care. 2012;35(5):1165–1170. doi: 10.2337/dc11-1307Drury PL, Cundy T. Glycemic management of type 2 diabetes mellitus. The New England journal of medicine. 2012;367(2):182. doi: 10.1056/NEJMc1205238#SA2Drury PL, Cundy T. Glycemic management of type 2 diabetes mellitus. The New England journal of medicine. 2012;367(2):182. doi: 10.1056/NEJMc1205238#SA2Shyng S-L, Nichols C. Octameric stoichiometry of the KATP channel complex. The Journal of general physiology. 1997;110(6):655–664.Shyng S-L, Nichols C. Octameric stoichiometry of the KATP channel complex. The Journal of general physiology. 1997;110(6):655–664.Ashcroft F, Gribble F. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42(8):903–919.Ashcroft F, Gribble F. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42(8):903–919.Hattersley A, Bruining J, Shield J, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric diabetes. 2009;10 Suppl 12:33–42. doi: 10.1111/j.1399-5448.2009.00571.xHattersley A, Bruining J, Shield J, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric diabetes. 2009;10 Suppl 12:33–42. doi: 10.1111/j.1399-5448.2009.00571.xPearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. New England Journal of Medicine. 2006;355(5):467–477.Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. New England Journal of Medicine. 2006;355(5):467–477.Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenetics and genomics. 2012;22(3):206–214. doi: 10.1097/FPC.0b013e32835001e7Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenetics and genomics. 2012;22(3):206–214. doi: 10.1097/FPC.0b013e32835001e7Qiu L, Na R, Xu R, et al. Quantitative assessment of the effect of KCNJ11 gene polymorphism on the risk of type 2 diabetes. PloS one. 2014;9(4):e93961. doi: 10.1371/journal.pone.0093961Qiu L, Na R, Xu R, et al. Quantitative assessment of the effect of KCNJ11 gene polymorphism on the risk of type 2 diabetes. PloS one. 2014;9(4):e93961. doi: 10.1371/journal.pone.0093961Gong B, Yu J, Li H, et al. The effect of KCNJ11 polymorphism on the risk of type 2 diabetes: a global meta-analysis based on 49 case-control studies. DNA and cell biology. 2012;31(5):801–810. doi: 10.1089/dna.2011.1445Gong B, Yu J, Li H, et al. The effect of KCNJ11 polymorphism on the risk of type 2 diabetes: a global meta-analysis based on 49 case-control studies. DNA and cell biology. 2012;31(5):801–810. doi: 10.1089/dna.2011.1445Qin LJ, Lv Y, Huang QY. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes. Genetics and molecular research: GMR. 2013;12(3):2990–3002. doi: 10.4238/2013.August.20.1Qin LJ, Lv Y, Huang QY. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes. Genetics and molecular research: GMR. 2013;12(3):2990–3002. doi: 10.4238/2013.August.20.1Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53(5):1360–1368Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53(5):1360–1368Gloyn AL, Hashim Y, Ashcroft SJ, et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabetic medicine: a journal of the British Diabetic Association. 2001;18(3):206–212.Gloyn AL, Hashim Y, Ashcroft SJ, et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabetic medicine: a journal of the British Diabetic Association. 2001;18(3):206–212.Klen J, Dolzan V, Janez A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European journal of clinical pharmacology. 2014;70(4):421–428. doi: 10.1007/s00228-014-1641-xKlen J, Dolzan V, Janez A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European journal of clinical pharmacology. 2014;70(4):421–428. doi: 10.1007/s00228-014-1641-xFeng Y, Mao G, Ren X, et al. Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients. Diabetes care. 2008;31(10):1939–1944. doi: 10.2337/dc07-2248Feng Y, Mao G, Ren X, et al. Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients. Diabetes care. 2008;31(10):1939–1944. doi: 10.2337/dc07-2248Zhang H, Liu X, Kuang H, et al. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes research and clinical practice. 2007;77(1):58–61. doi: 10.1016/j.diabres.2006.10.021Zhang H, Liu X, Kuang H, et al. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes research and clinical practice. 2007;77(1):58–61. doi: 10.1016/j.diabres.2006.10.021Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European journal of internal medicine. 2012;23(3):245–249. doi: 10.1016/j.ejim.2011.10.018Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European journal of internal medicine. 2012;23(3):245–249. doi: 10.1016/j.ejim.2011.10.018Sesti G, Laratta E, Cardellini M, et al. The E23K Variant of KCNJ11 Encoding the Pancreatic β-Cell Adenosine 5′-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2006;91(6):2334–2339. doi: 10.1210/jc.2005-2323Sesti G, Laratta E, Cardellini M, et al. The E23K Variant of KCNJ11 Encoding the Pancreatic β-Cell Adenosine 5′-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2006;91(6):2334–2339. doi: 10.1210/jc.2005-2323

The authors declare that there are no conflicts of interest present.